NASDAQ:APMD Apnimed (APMD) Stock Price, News & Analysis $17.25 -0.20 (-1.15%) As of 04:00 PM Eastern Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Apnimed Stock (NASDAQ:APMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Apnimed alerts:Sign Up Key Stats Today's Range$16.54▼$17.6150-Day Range$14.16▼$29.0052-Week Range$13.88▼$35.29Volume197,616 shsAverage Volume448,263 shsMarket Capitalization$718.13 millionP/E Ratio6.56Dividend YieldN/APrice Target$50.33Consensus RatingModerate Buy Company Overview Apnimed is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea. The company aims to offer drug-based treatment options for people who may not use or benefit from existing device-based therapies. Its lead candidate, AD109, is an investigational oral combination of atomoxetine and aroxybutynin (oxybutynin) designed to help maintain upper-airway muscle activity during sleep. Apnimed has evaluated AD109 in clinical trials for obstructive sleep apnea; it is not an approved treatment. Apnimed is based in Cambridge, Massachusetts. Its research and development efforts are centered on advancing pharmaceutical treatments for sleep apnea and related conditions.AI Generated. May Contain Errors. Read More Apnimed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreAPMD MarketRank™: 3.94144144144 of 5 starsApnimed scored higher than 79% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingApnimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialApnimed has a consensus price target of $50.33, representing about 191.8% upside from its current price of $17.25.Amount of Analyst CoverageApnimed has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Apnimed's stock forecast and price target. Earnings and Valuation0.7 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Apnimed are expected to decrease in the coming year, from ($0.24) to ($3.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apnimed is 6.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.65. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.81% of the float of Apnimed has been sold short.Short Interest Ratio / Days to CoverApnimed has a short interest ratio ("days to cover") of 4.54.Change versus previous monthShort interest in Apnimed has recently decreased by 12.03%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApnimed does not currently pay a dividend.Dividend GrowthApnimed does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.36 News SentimentApnimed has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Apnimed this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for APMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Apnimed to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Apnimed insiders have not sold or bought any company stock.Percentage Held by InstitutionsApnimed has minimal institutional ownership at this time.Read more about Apnimed's insider trading history. Receive APMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apnimed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APMD Stock News HeadlinesNew National Survey Found Many People With Sleep Apnea Struggle to Stay on TreatmentNovember 19 at 8:00 AM | globenewswire.comApnimed, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 16 at 1:23 PM | marketscreener.comMWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 19 at 1:00 AM | Base Camp Trading (Ad)Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 16 at 8:00 AM | globenewswire.comApnimed, Inc. (NASDAQ:APMD) Stock Has Average Target Price of $50.33 According to AnalystsNovember 16 at 1:33 AM | americanbankingnews.comApnimed: Top Pick Biotech, Treating OSA With A Pill, Initiating With A BuyNovember 12, 2026 | seekingalpha.comApnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 5, 2026 | globenewswire.comApnimed (APMD): Could Oxnimbi Open New Era In Oral Sleep Apnea Treatment?November 2, 2026 | rttnews.comSee More Headlines APMD Stock Analysis - Frequently Asked Questions How have APMD shares performed this year? Apnimed's stock was trading at $25.00 on July 31, 2026. Since then, APMD shares have decreased by 31.0% and is now trading at $17.25. How were Apnimed's earnings last quarter? Apnimed, Inc. (NASDAQ:APMD) released its earnings results on Monday, November, 16th. The company reported ($1.05) earnings per share for the quarter. The firm had revenue of $2.48 million for the quarter. When did Apnimed IPO? Apnimed (APMD) raised $192 million in an initial public offering (IPO) on Friday, July 31st 2026. The company issued 12,000,000 shares at a price of $16.00 per share. When does the company's lock-up period expire? Apnimed's lock-up period expires on Wednesday, January 27th. Apnimed had issued 12,000,000 shares in its public offering on July 31st. The total size of the offering was $192,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period. Who are Apnimed's major shareholders? Top institutional shareholders of Apnimed include Integral Health Asset Management LLC (0.54%) and Bellevue Group AG (0.01%). View institutional ownership trends. How do I buy shares of Apnimed? Shares of APMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/16/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:APMD CIK1745648 Webwww.apnimed.com Phone(617) 500-8880FaxN/AEmployees81Year FoundedN/APrice Target and Rating Average Price Target for Apnimed$50.33 High Price Target$60.00 Low Price Target$41.00 Potential Upside/Downside+191.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio6.56 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.19 Quick Ratio5.19 Sales & Book Value Annual Sales$115.12 million Price / Sales6.24 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares41,631,000Free FloatN/AMarket Cap$718.13 million OptionableOptionable BetaN/A The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:APMD) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredAlpha Oracle Signal drops to $7 for Black FridayThe Alpha Oracle Signal trading system is on sale for just $7 during a limited Black Friday deal. Others paid ...TradeWins | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apnimed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apnimed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.